Home>Topics>Companies>Orexigen Therapeutics

Orexigen Therapeutics

  1. All
  2. Commentary
  3. Headlines
  1. Orexigen Launches Contrave - Watch For Traction

    Headlines

    Mon, 20 Oct 2014

    Orexigen Launches Contrave - Watch For Traction

  2. Are People Too Concerned About Orexigen's Contrave Label?

    Headlines

    Sun, 19 Oct 2014

    30, 2014. With its FDA Approval on September 11th 2014, Orexigen 's (NASDAQ: OREX ) Contrave became only the third anti-obesity drug to be ..... NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has tanked, dropping nearly 35% from its pre-approval

  3. Belviq Sales Dip: What To Watch For Ahead

    Headlines

    Fri, 17 Oct 2014

    dipped back down again over the last week and-a half. Lastly, competitor Orexigen (NASDAQ: OREX ) is set to launch Contrave, a competing product. The Orexigen launch of Contrave is a double edged sword. On one hand they will be competing

  4. What To Watch For As Orexigen's Launch Approaches

    Headlines

    Thu, 16 Oct 2014

    By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced today that the company is set to bank $100 million ..... denying that Wall Street will be there as well. When launched, Orexigen will join Arena (NASDAQ: ARNA ) and Vivus (NASDAQ: VVUS

  5. Orexigen earns $70M milestone

    Headlines

    Wed, 15 Oct 2014

    Orexigen Therapeutics ( OREX +6.4% ) earns a $70M milestone payment from Takeda Pharmaceuticals ..... earned a $30M milestone triggered by FDA approval on October 7. Orexigen expects to end 2014 with ~$190M in quick assets. Post your comment

  6. Orexigen On A Tear - In The Wrong Direction

    Headlines

    Tue, 7 Oct 2014

    Osborne : With the approval of an anti-obesity drug, it could be very easy for an investor new in the sector to think that Orexigen (NASDAQ: OREX ) is a "no-brainer." After all, two thirds of the country is either overweight or obese and a dug that could help combat

  7. It Takes Less Than 15 Minutes To Buy VVUS Shares!

    Headlines

    Fri, 19 Sep 2014

    blockbuster potential in excess of a billion dollars per year. Qsymia will compete with Belviq by Arena (NASDAQ: ARNA ). Orexigen 's (NASDAQ: OREX ) drug was recently approved by the FDA, with the requirement for more safety trials like Qysimia. Discussion of the earnings

  8. Orexigen Therapeutics ( OREX ) Presents at Bank of America Merrill Lynch Global Healthcare Conference (Transcript)

    Headlines

    Thu, 18 Sep 2014

    By SA Transcripts : Orexigen Therapeutics , Inc . (NASDAQ: OREX ) Bank of America Merrill Lynch ..... s a pleasure for me to host Orexigen . Mark Booth, Chief Commercial ..... President of Takeda North America, Orexigen ’s current partner for their

  9. Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away

    Headlines

    Tue, 16 Sep 2014

    By Long Term Bio : Orexigen Therapeutics (NASDAQ: OREX ) received FDA approval for ..... help reduce their weight. Orexigen Therapeutics has been struggling to receive ..... The FDA had cited that Orexigen will need to run an additional

  10. Orexigen Falls After Approval - Why?

    Headlines

    Mon, 15 Sep 2014

    By Spencer Osborne : Orexigen (NASDAQ: OREX ) shares have tumbled upon FDA approval of the anti-obesity ..... sector has not performed like many thought it would. Prior to Orexigen getting FDA approval there were two other players in the space

« Prev1234Next »
Content Partners